"BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, exploring divestment options for each site, including partial or total sales."
"In 2026, BioNTech anticipates lower Covid-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets."
BioNTech plans to cease operations at three manufacturing sites in Germany by 2027 and one in Singapore by early next year, impacting 1,860 jobs. The company aims to save up to 500 million euros annually by 2029. BioNTech reported a 35 percent drop in sales to 118.1 million euros and a widened loss of 531.9 million euros. The company anticipates lower Covid-19 vaccine revenues in 2026 compared to 2025, as it shifts focus towards cancer treatments.
Read at The Local Germany
Unable to calculate read time
Collection
[
|
...
]